{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:33:11Z","timestamp":1776720791260,"version":"3.51.2"},"reference-count":140,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jtho.2018.01.002","type":"journal-article","created":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T03:33:23Z","timestamp":1515641603000},"page":"301-322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Progress in the Management of Advanced Thoracic Malignancies in 2017"],"prefix":"10.1016","volume":"13","author":[{"given":"Roberto","family":"Ferrara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mezquita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2018.01.002_bib1","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1200\/JCO.2017.72.5069","article-title":"Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","article-title":"Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial","volume":"18","author":"Heery","year":"2017","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib3","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/JCO.2017.35.15_suppl.8521","article-title":"A\u00a0phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor","volume":"35","author":"Cho","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2018.01.002_bib5","first-page":"v605","article-title":"Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase II trial","volume":"28","author":"Zalcman","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2018.01.002_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2018.01.002_bib8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 13","key":"10.1016\/j.jtho.2018.01.002_bib9","article-title":"Abstract CT077. Five-year follow-up from the CA209\u2013003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): clinical characteristics of long-term survivors","volume":"77","author":"Brahmer","year":"2017","journal-title":"Cancer Res"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2018.01.002_bib10","first-page":"v460","article-title":"Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)","volume":"28","author":"Spiegel","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2018.01.002_bib12","doi-asserted-by":"crossref","first-page":"v460","DOI":"10.1093\/annonc\/mdx380.001","article-title":"Clinical efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: results from the randomized OAK study","volume":"28","author":"Gadgeel","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2018.01.002_bib13","doi-asserted-by":"crossref","first-page":"v460","DOI":"10.1093\/annonc\/mdx380","article-title":"Blood-based biomarkers for cancer immunotherapy: tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy","volume":"28","author":"Gandara","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib14","doi-asserted-by":"crossref","first-page":"9086","DOI":"10.1200\/JCO.2017.35.15_suppl.9086","article-title":"Exposure-response and PD-L1 expression analysis of second-line avelumab in patients with advanced NSCLC: data from the JAVELIN Solid Tumor trial","volume":"35","author":"Gulley","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib15","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","author":"Haratani","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib16","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2018.01.002_bib17","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2018.01.002_bib18","first-page":"v460","article-title":"Italian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: real-world results in never smokers and EGFR positive patients","volume":"28","author":"Garassino","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2018.01.002_bib19","doi-asserted-by":"crossref","first-page":"ii28","DOI":"10.1093\/annonc\/mdx091.002","article-title":"Durvalumab in\u2009\u2265\u20093rd-line EGFR mutant\/ALK+, locally advanced or metastatic NSCLC: results from the phase 2 ATLANTIC study","volume":"28","author":"Garassino","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib20","unstructured":"Costa E, Felip E, Reck M, et\u00a0al. OA17.02 Updated efficacy results from the BIRCH study: first-line atezolizumab therapy in PD-L1\u2013selected patients with advanced NSCLC. Paper presented at: IASLC 18th World Conference on Lung Cancer. October 15\u201318, 2017; Yokohama, Japan."},{"key":"10.1016\/j.jtho.2018.01.002_bib21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.lungcan.2017.07.022","article-title":"Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer","volume":"111","author":"Hata","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.01.002_bib22","unstructured":"ClinicalTrials.gov. A study of nivolumab\u00a0+ chemotherapy or nivolumab\u00a0+ ipilimumab versus chemotherapy in patients with EGFR mutation, T790M negative NSCLC who have failed 1L EGFR TKI therapy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02864251. Accessed November 6, 2017."},{"key":"10.1016\/j.jtho.2018.01.002_bib23","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.01.002_bib24","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib25","doi-asserted-by":"crossref","unstructured":"Ferrara R, Caramella C, Texier M, et\u00a0al. MA10.11 Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (Pts) treated with anti PD1\/PD-L1 agents (IO). Paper presented at: IASLC 18th World Conference on Lung Cancer. October 15\u201318, 2017; Yokohama, Japan.","DOI":"10.1093\/annonc\/mdx380.009"},{"key":"10.1016\/j.jtho.2018.01.002_bib26","unstructured":"Brahmer J, Abreu Rodriguez D, Robinson. AG OA 17.06. Updated analysis of KEYNOTE-024: pembrolizumab vs platinum-based chemotherapy for advanced NSCLC with PD-L1 TPS \u226550%. Paper presented at: IASLC 18th World Conference on Lung Cancer. October 15\u201318, 2017; Yokohama, Japan."},{"key":"10.1016\/j.jtho.2018.01.002_bib27","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 4","key":"10.1016\/j.jtho.2018.01.002_bib28","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/S1556-0864(16)30300-8","article-title":"191TiP. MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC","volume":"11","author":"Peters","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib29","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for\u00a0advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label\u00a0KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib30","doi-asserted-by":"crossref","unstructured":"Borghaei H, Langer CL, Gadgeel S, et\u00a0al. OA 17.01. Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC: KEYNOTE-021 cohort G update. Paper presented at: IASLC 18th World Conference on Lung Cancer. October 15\u201318, 2017; Yokohama, Japan.","DOI":"10.1016\/j.jtho.2017.09.427"},{"key":"10.1016\/j.jtho.2018.01.002_bib31","unstructured":"ClinicalTrials.gov. Study of platinum+pemetrexed chemotherapy with or without pembrolizumab (MK-3475) in participants with first line metastatic non-squamous non-small cell lung cancer (MK-3475-189\/KEYNOTE-189). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02578680. Accessed November 6, 2017."},{"key":"10.1016\/j.jtho.2018.01.002_bib32","doi-asserted-by":"crossref","unstructured":"Reck M, Socinski MA, Cappuzzo F, et\u00a0al. Primary PFS and safety analyses of a randomized phase III study of carboplatin\u00a0+ paclitaxel\u00a0+\/\u2212 bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMPOWER150). LBA 1_PR. Abstract presented at: ESMO Immuno Oncology Congress; December 7\u201310, 2017; Geneva, Switzerland.","DOI":"10.1016\/S1556-0864(18)30409-X"},{"key":"10.1016\/j.jtho.2018.01.002_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib34","doi-asserted-by":"crossref","unstructured":"Juergens RJ, Hellmann MD, Brahmer J, et\u00a0al. OA 17.03. First-line nivolumab plus platinum-based doublet chemotherapy for advanced NSCLC: CheckMate 012 3-year update. Paper presented at: IASLC 18th World Conference on Lung Cancer. October 15\u201318, 2017; Yokohama, Japan.","DOI":"10.1016\/j.jtho.2017.09.429"},{"key":"10.1016\/j.jtho.2018.01.002_bib35","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2018.01.002_bib36","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1111\/cas.13410","article-title":"Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients","volume":"108","author":"Liu","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2018.01.002_bib37","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib38","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib39","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdw611","article-title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","volume":"28","author":"Paz-Ares","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib40","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib41","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1200\/JCO.2017.35.15_suppl.9017","article-title":"Osimertinib compared to docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small cell lung cancer","volume":"35","author":"Nie","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib42","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1200\/JCO.2017.73.9250","article-title":"Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses","volume":"35","author":"Mok","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib43","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(17)30129-7","article-title":"Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial","volume":"5","author":"Rosell","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2018.01.002_bib44","doi-asserted-by":"crossref","unstructured":"Elamin YY, Robichaux J, Lam VK, et\u00a0al. OA 12.01. The preclinical and clinical activity of poziotinib, a potent, selective inhibitor of EGFR exon 20 mutant NSCLC. Paper presented at: IASLC 18th World Conference on Lung Cancer. October 15\u201318, 2017; Yokohama, Japan.","DOI":"10.1016\/j.jtho.2017.09.394"},{"key":"10.1016\/j.jtho.2018.01.002_bib45","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/bjc.2016.456","article-title":"A\u00a0phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations","volume":"116","author":"Yang","year":"2017","journal-title":"Br J Cancer"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib46","doi-asserted-by":"crossref","first-page":"9005","DOI":"10.1200\/JCO.2017.35.15_suppl.9005","article-title":"CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: data from a randomized phase III trial (AURA3)","volume":"35","author":"Mok","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib47","unstructured":"ClinicalTrials.gov. Osimertinib treatment on EGFR T790M plasma positive NSCLC patients (APPLE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02856893. Accessed November 6, 2017."},{"key":"10.1016\/j.jtho.2018.01.002_bib48","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1093\/annonc\/mdx288","article-title":"Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions","volume":"28","author":"Mayo-de-Las-Casas","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib49","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/annonc\/mdx017","article-title":"Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA","volume":"28","author":"Remon","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib50","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer","volume":"34","author":"Oxnard","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib51","doi-asserted-by":"crossref","first-page":"9018","DOI":"10.1200\/JCO.2017.35.15_suppl.9018","article-title":"Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial","volume":"35","author":"Thress","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib52","doi-asserted-by":"crossref","unstructured":"Oxnard GR, Hu Y, Mileham KF et\u00a0al. OA 09.02. Osimertinib resistance mediated by loss of EGFR T790M is associated with early resistance and competing resistance mechanisms. Paper presented at: IASLC 18th World Conference on Lung Cancer. October 15\u201318, 2017; Yokohama, Japan.","DOI":"10.1016\/j.jtho.2017.09.376"},{"key":"10.1016\/j.jtho.2018.01.002_bib53","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2018.01.002_bib54","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2016.71.9096","article-title":"Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas","volume":"35","author":"Lee","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib55","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","article-title":"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics","volume":"12","author":"Arcila","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2018.01.002_bib56","doi-asserted-by":"crossref","first-page":"21903","DOI":"10.18632\/oncotarget.15746","article-title":"Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study","volume":"8","author":"Duruisseaux","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2018.01.002_bib57","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdw693","article-title":"Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer","volume":"28","author":"Woo","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib58","doi-asserted-by":"crossref","first-page":"9010","DOI":"10.1200\/JCO.2017.35.15_suppl.9010","article-title":"Association of ALK resistance mutations by EML4-ALK variant (v3 vs. non-v3) in ALK+ non-small cell lung cancer (NSCLC)","volume":"35","author":"Ou","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib59","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2015.65.8732","article-title":"Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer","volume":"34","author":"Yoshida","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib60","first-page":"9060","article-title":"Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status","volume":"35","author":"Gettinger","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2018.01.002_bib61","first-page":"v605","article-title":"Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: updated results from PROFILE 1014","volume":"28","author":"Mok","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib62","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib63","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2018.01.002_bib64","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jtho.2017.07.005","article-title":"ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in Fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC)","volume":"12","author":"Cho","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2018.01.002_bib65","first-page":"v605","article-title":"Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)","volume":"28","author":"Novello","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib66","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial","volume":"35","author":"Kim","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib67","doi-asserted-by":"crossref","unstructured":"Solomon BJ, Shaw A, Ou SH, et\u00a0al. OA 05.06. Phase 2 study of lorlatinib in patients with advanced ALK+ROS1+ non-small-cell lung cancer. Paper presented at: IASLC 18th World Conference on Lung Cancer. October 15\u201318, 2017; Yokohama, Japan.","DOI":"10.1016\/j.jtho.2017.09.351"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib68","first-page":"9056","article-title":"Plasma genotyping of patients enrolled on the expansion phase I\/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC)","volume":"35","author":"Horn","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2018.01.002_bib69","first-page":"v605","article-title":"Alectinib vs crizotinib in treatment-naive ALK+ NSCLC: CNS efficacy results from the ALEX study","volume":"28","author":"Gadgeel","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib70","unstructured":"ClinicalTrials.gov. ALTA-1L study: a phase 3 study of brigatinib versus crizotinib in ALK-positive advanced non-small cell lung cancer patients. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02737501. Accessed November 6, 2017."},{"key":"10.1016\/j.jtho.2018.01.002_bib71","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2018.01.002_bib72","unstructured":"ClinicalTrials.gov. A study of lorlatinib versus crizotinib in first line treatment of patients with ALK-positive NSCLC. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03052608. Accessed November 6, 2017."},{"key":"10.1016\/j.jtho.2018.01.002_bib73","unstructured":"ClinicalTrials.gov. eXalt3: study comparing X-396 (ensartinib) to crizotinib in ALK positive non-small cell lung cancer (NSCLC) patients. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02767804. Accessed November 6, 2017."},{"key":"10.1016\/j.jtho.2018.01.002_bib74","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2018.01.002_bib75","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","article-title":"Open-label, multicenter, phase II study of ceritinib in patients with non\u2013small-cell lung cancer harboring ROS1 rearrangement","volume":"35","author":"Lim","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib76","doi-asserted-by":"crossref","unstructured":"Ahn MJ, Cho B, Siena S, et\u00a0al. OA 14.06. Entrectinib in patients with locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). Paper presented at: IASLC 18th World Conference on Lung Cancer. October 15\u201318, 2017; Yokohama, Japan.","DOI":"10.1016\/j.jtho.2017.09.411"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib77","doi-asserted-by":"crossref","first-page":"9072","DOI":"10.1200\/JCO.2016.34.15_suppl.9072","article-title":"Frequency and spectrum of ROS1 resistance mutations in ROS1-positive lung cancer patients progressing on crizotinib","volume":"34","author":"Gainor","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib78","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","article-title":"Acquired resistance to crizotinib from a mutation in CD74-ROS1","volume":"368","author":"Awad","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2018.01.002_bib79","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1158\/1078-0432.CCR-16-0917","article-title":"Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1- and ALK-rearranged lung cancers","volume":"22","author":"Facchinetti","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.01.002_bib80","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/1078-0432.CCR-15-1601","article-title":"Identification of existing drugs that effectively target NTRK1 and ROS1 rearrangements in lung cancer","volume":"23","author":"Chong","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.01.002_bib81","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1158\/1078-0432.CCR-14-1385","article-title":"Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer","volume":"21","author":"Katayama","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.01.002_bib82","unstructured":"ClinicalTrials.gov. Cabozantinib in patients with RET fusion-positive advanced non-small cell lung cancer and those with other genotypes: ROS1 or NTRK fusions or increased MET or AXL activity. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01639508. Accessed November 6, 2017."},{"key":"10.1016\/j.jtho.2018.01.002_bib83","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/nm.3352","article-title":"Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer","volume":"19","author":"Vaishnavi","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2018.01.002_bib84","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib85","doi-asserted-by":"crossref","first-page":"LBA2501","DOI":"10.1200\/JCO.2017.35.15_suppl.LBA2501","article-title":"The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers","volume":"35","author":"Hyman","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2018.01.002_bib86","first-page":"v605","article-title":"Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E\u2013mutant metastatic non-small cell lung cancer","volume":"28","author":"Planchard","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib87","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2017.3438","article-title":"Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial","volume":"317","author":"J\u00e4nne","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2018.01.002_bib88","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-2600(16)30322-8","article-title":"Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial","volume":"5","author":"Yoh","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2018.01.002_bib89","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/annonc\/mdw559","article-title":"Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib90","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2016.69.2160","article-title":"Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung","volume":"35","author":"Spigel","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib91","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1200\/JCO.2017.35.15_suppl.9019","volume":"35","author":"Scagliotti","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib92","doi-asserted-by":"crossref","unstructured":"Ahn MJ, Han JY, Sequist L, et\u00a0al. OA 09.03. TATTON Ph Ib expansion cohort: osimertinib plus savolitinib for Pts with EGFR-mutant MET-amplified NSCLC after progression on prior EGFR-TKI. Paper presented at: IASLC 18th World Conference on Lung Cancer. October 15\u201318, 2017; Yokohama, Japan.","DOI":"10.1016\/j.jtho.2017.09.377"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib93","doi-asserted-by":"crossref","first-page":"9070","DOI":"10.1200\/JCO.2017.35.15_suppl.9070","article-title":"A\u00a0single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: the ETOP NICHE trial","volume":"35","author":"Smit","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib94","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1200\/JCO.2017.35.15_suppl.8509","article-title":"Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC)","volume":"35","author":"Stinchcombe","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib95","doi-asserted-by":"crossref","unstructured":"Li B, Shen L, Buonocore D, et\u00a0al. OA 14.05. Phase 2 basket trial of ado-trastuzumab emtansine in patients with HER2 mutant or amplified lung cancers. Paper presented at: IASLC 18th World Conference on Lung Cancer. October 15\u201318, 2017; Yokohama, Japan.","DOI":"10.1016\/j.jtho.2017.09.410"},{"key":"10.1016\/j.jtho.2018.01.002_bib96","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib97","doi-asserted-by":"crossref","first-page":"9075","DOI":"10.1200\/JCO.2017.35.15_suppl.9075","article-title":"Updated survival of patients (pts) with previously treated BRAF V600E\u2013mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D\u00a0+ trametinib (T) in the phase II BRF113928 study","volume":"35","author":"Planchard","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib98","unstructured":"ClinicalTrials.gov. A study of abemaciclib (LY2835219) in participants with previously treated KRAS mutated lung cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02152631. Accessed November 6, 2017."},{"key":"10.1016\/j.jtho.2018.01.002_bib99","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.jtho.2018.01.002_bib100","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl 6","key":"10.1016\/j.jtho.2018.01.002_bib101","article-title":"Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung","volume":"27","author":"Velcheti","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib102","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.2016.70.9352","article-title":"Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry","volume":"35","author":"Gautschi","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib103","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtho.2017.10.021","article-title":"Clinical and translational implications of RET rearrangements in non-small cell lung cancer","volume":"13","author":"Ferrara","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib104","doi-asserted-by":"crossref","first-page":"9068","DOI":"10.1200\/JCO.2016.34.15_suppl.9068","article-title":"MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers","volume":"34","author":"Somwar","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib105","doi-asserted-by":"crossref","first-page":"e18528","DOI":"10.1200\/jco.2015.33.15_suppl.e18528","article-title":"The clinical characteristics of RET rearranged lung adenocarcinoma patients","volume":"33","author":"Kim","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib106","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.lungcan.2015.06.021","article-title":"Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI","volume":"89","author":"Klempner","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.01.002_bib107","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jtho.2015.09.016","article-title":"Clinicopathological characteristics of RET rearranged lung cancer in European patients","volume":"11","author":"Michels","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib108","doi-asserted-by":"crossref","first-page":"9069","DOI":"10.1200\/JCO.2016.34.15_suppl.9069","article-title":"Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion","volume":"34","author":"Cascone","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib109","doi-asserted-by":"crossref","unstructured":"Velcheti M, Bauer TM, Subbiah V et\u00a0al. OA 12.07. LOXO-292, a potent, highly selective RET inhibitor, in MKI-resistant RET fusion-positive lung cancer patients with and without brain metastases. Paper presented at: IASLC 18th World Conference on Lung Cancer. October 15\u201318, 2017; Yokohama, Japan.","DOI":"10.1016\/j.jtho.2017.09.399"},{"key":"10.1016\/j.jtho.2018.01.002_bib110","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.01.002_bib111","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2353\/ajpath.2010.100217","article-title":"Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas","volume":"177","author":"Matsubara","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jtho.2018.01.002_bib112","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/annonc\/mdv288","volume":"26","author":"Yoshioka","year":"2015","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib113","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1200\/JCO.2017.35.15_suppl.9020","article-title":"MET amplification (amp) as a resistance mechanism to osimertinib","volume":"35","author":"Piotrowska","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib114","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1200\/JCO.2017.35.15_suppl.8511","article-title":"Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC)","volume":"35","author":"Awad","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib115","article-title":"Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)","volume":"34","author":"Drilon","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib116","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/JTO.0b013e3181f26266","article-title":"The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data","volume":"5","author":"Liu","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib117","first-page":"5238","article-title":"HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin","volume":"9","author":"Heinm\u00f6ller","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib118","doi-asserted-by":"crossref","first-page":"9071","DOI":"10.1200\/JCO.2017.35.15_suppl.9071","article-title":"Afatinib in patients with metastatic HER2-mutant lung cancers: an international multicenter study","volume":"35","author":"Lai","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib119","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","article-title":"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors","volume":"26","author":"Kris","year":"2015","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib120","doi-asserted-by":"crossref","first-page":"s358","DOI":"10.1016\/j.jtho.2016.11.398","article-title":"Neratinib \u00b1 tlimus in HER2-mutant lung cancers: an international, randomized phase II study","volume":"12","author":"Gandhi","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib121","doi-asserted-by":"crossref","first-page":"9002","DOI":"10.1200\/JCO.2017.35.15_suppl.9002","article-title":"Efficacy of the addition of cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): a joint analysis of the multicenter, randomized phase III MILES-3 and MILES-4 studies","volume":"35","author":"Gridelli","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib122","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1200\/JCO.2017.35.15_suppl.9004","volume":"35","author":"Benounna","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib123","doi-asserted-by":"crossref","first-page":"S284","DOI":"10.1016\/j.jtho.2016.11.288","article-title":"Prolonged OS of patients exposed to weekly paclitaxel and bevacizumab: impact of the cross-over in the IFCT-1103 ULTIMATE study","volume":"12","author":"Cortot","year":"2017","journal-title":"J\u00a0Thor Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib124","unstructured":"Reck M, Shepherd F, Perol M, et\u00a0al. MA 03.06. Effect of 2L ramucirumab after rapid time to progression on 1L therapy: subgroup analysis of REVEL in advanced NSCLC. Paper presented at: IASLC 18th World Conference on Lung Cancer. October 15\u201318, 2017; Yokohama, Japan."},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib125","doi-asserted-by":"crossref","first-page":"9003","DOI":"10.1200\/JCO.2017.35.15_suppl.9003","article-title":"IFCT-GFPC-1101 trial: a multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSCLC)","volume":"35","author":"Perol","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib126","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib127","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib128","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2017.35.15_suppl.8503","article-title":"Nivolumab (nivo) \u00b1 ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): first report of a randomized expansion cohort from CheckMate 032","volume":"35","author":"Hellmann","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib129","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib130","unstructured":"ClinicalTrials.gov. Study of rovalpituzumab tesirine (SC16LD6.5) for third-line and later treatment of subjects with relapsed or refractory delta-like protein 3-expressing small cell lung cancer (TRINITY). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02674568. Accessed November 6, 2017."},{"issue":"suppl 5","key":"10.1016\/j.jtho.2018.01.002_bib131","article-title":"Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2\/3) in combination with etoposide and platinum (EP) in patients with untreated extensive small cell lung cancer","volume":"28","author":"Daniel","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib132","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1200\/JCO.2017.35.15_suppl.8505","article-title":"Randomized trial of cisplatin and etoposide in combination with veliparib or placebo for extensive stage small cell lung cancer: ECOG-ACRIN 2511 study","volume":"35","author":"Owonikoko","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib133","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.1200\/JCO.2017.35.15_suppl.8568","article-title":"Trilaciclib (G1T28): a cyclin dependent kinase 4\/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)\u2014phase 1b results","volume":"35","author":"Lima","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2018.01.002_bib134","doi-asserted-by":"crossref","first-page":"v539","DOI":"10.1093\/annonc\/mdx386.003","article-title":"Activity of lurbinectedin as single agent and in combination in patients with advanced small cell lung cancer (SCLC)","volume":"28","author":"Garcia Olmedo","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib135","unstructured":"ClinicalTrials.gov. Clinical trial of lurbinectedin (PM01183)\/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02566993. Accessed November 6, 2017."},{"key":"10.1016\/j.jtho.2018.01.002_bib136","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib137","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib138","doi-asserted-by":"crossref","first-page":"8553","DOI":"10.1200\/JCO.2017.35.15_suppl.8553","article-title":"Expansion study of ADI-PEG 20, pemetrexed and cisplatin in patients with ASS1-deficient malignant pleural mesothelioma (TRAP)","volume":"35","author":"Phillips","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.01.002_bib139","unstructured":"ClinicalTrials.gov. Ph 2\/3 study in subjects with MPM w\/low ASS 1 expression to assess ADI-PEG 20 with pemetrexed and cisplatin. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02709512. Accessed November 6, 2017."},{"issue":"suppl","key":"10.1016\/j.jtho.2018.01.002_bib140","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1200\/JCO.2017.35.15_suppl.8573","article-title":"Pembrolizumab in patients with recurrent thymic carcinoma: results from a phase II study","volume":"35","author":"Giaccone","year":"2017","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418300029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418300029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T13:08:11Z","timestamp":1603631291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086418300029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":140,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1556086418300029"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2018.01.002","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in the Management of Advanced Thoracic Malignancies in 2017","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2018.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}